Cargando…
The potential of Atorvastatin for chronic lung diseases therapy
Atorvastatin (ATO) is of the statin class and is used as an orally administered lipid-lowering drug. ATO is a reversible synthetic competitive inhibitor of 3-hydroxy-3-methyl-glutaryl-CoA (HMG-CoA) reductase thus leading to a reduction in cholesterol synthesis. It has recently been demonstrated that...
Autor principal: | Tulbah, Alaa S. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7679442/ https://www.ncbi.nlm.nih.gov/pubmed/33250642 http://dx.doi.org/10.1016/j.jsps.2020.08.025 |
Ejemplares similares
-
Design and Characterization of Atorvastatin Dry Powder Formulation as a potential Lung Cancer Treatment
por: Tulbah, Alaa S., et al.
Publicado: (2021) -
In vitro bio-characterization of solid lipid nanoparticles of favipiravir in A549 human lung epithelial cancer cells
por: Tulbah, Alaa S.
Publicado: (2023) -
Comparing the combination therapy of ezetimibe and atorvastatin with atorvastatin monotherapy for regulating blood lipids: a systematic review and meta-analyse
por: Ai, Cong, et al.
Publicado: (2018) -
Real-world Evidence for Adherence and Persistence with Atorvastatin Therapy
por: Tsioufis, Konstantinos, et al.
Publicado: (2021) -
Assessment and characteristics of Erenumab therapy on migraine management
por: Saeed, Haitham, et al.
Publicado: (2022)